Lymphangiomyomatosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Lymphangiomyomatosis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {...") |
No edit summary |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Lymphangiomyomatosis}} | {{Lymphangiomyomatosis}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Overview== | |||
==Future or Investigational Therapies== | |||
*[[Doxycycline]] has been proposed as a treatment with minimal side-effects.<ref>{{cite journal | title=Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs | author=Moses MA, Harper J, Folkman J | journal=New Engl J Med | year=2006 | volume=354 | pages=2621–22 | issue=24 }}</ref> | |||
*[[Sirolimus]] is being tested for the treatment of LAM. The MILES Trial (Multicenter International LAM Efficacy of Sirolimus Trial) is now underway. The first site, the University of Cincinnati, is open for enrollment. The National Institutes of Health will open enrollment soon. The MILES Trial is randomized, double-blinded, and placebo-controlled. The objective of the Trial is to determine if sirolimus has a beneficial effect on lung function in LAM patients. | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category: Disease]] | [[Category: Disease]] | ||
[[Category: Hematology]] | [[Category: Hematology]] | ||
Latest revision as of 18:00, 24 August 2015
Template:Lymphangiomyomatosis Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Future or Investigational Therapies
- Doxycycline has been proposed as a treatment with minimal side-effects.[1]
- Sirolimus is being tested for the treatment of LAM. The MILES Trial (Multicenter International LAM Efficacy of Sirolimus Trial) is now underway. The first site, the University of Cincinnati, is open for enrollment. The National Institutes of Health will open enrollment soon. The MILES Trial is randomized, double-blinded, and placebo-controlled. The objective of the Trial is to determine if sirolimus has a beneficial effect on lung function in LAM patients.
References
- ↑ Moses MA, Harper J, Folkman J (2006). "Doxycycline Treatment for Lymphangioleiomyomatosis with Urinary Monitoring for MMPs". New Engl J Med. 354 (24): 2621&ndash, 22.